APP访问

下载APP

关闭

暗流涌动!为摧毁中国 老美几天干了这么多事

作者:
2020-02-18 10:47:27

为了进一步证实我的推测,我继续贴上原文,并配翻译。

Two researchers from the University of North Carolina Gillings School of Global Public Health have been awarded a grant for more than $6 million to accelerate the development of a promising new drug in the fight against deadly coronaviruses.

北卡罗莱纳大学Gillings全球公共卫生学院的两名研究人员获得了600多万美元的资助,以加速开发一种有前途的新药,对抗致命的冠状病毒。

Ralph S. Baric, PhD, professor, and Timothy Sheahan, PhD, research assistant professor, both in the Department of Epidemiology at the Gillings School, are co-principal investigators for the grant. Awarded by the National Institute of Allergy and Infectious Diseases, “partnership grants” are designed to forge collaborations between experts from industry and academia to develop tools in the fight against high-priority emerging pathogens such as Middle East Respiratory Syndrome coronavirus (MERS-CoV), Zika virus and Ebola virus.

巴里克教授和Sheahan博士都是在Gillings学院的流行病学系,是该拨款的共同首席研究员。

由NIAID所颁发的“合作拨款奖”旨在促进产业界和学术界之间的合作,以开发工具,对抗中东呼吸综合征冠状病毒(MERS-CoV)、寨卡病毒和埃博拉病毒等高度优先的新发病原体。

The partnership grant awarded to Baric and Sheahan establishes a collaboration between the Gillings School and Gilead Sciences Inc.,

Vanderbilt University Medical Center and the University of Texas Medical Branch.

The collaboration builds upon an earlier partnership between the Gillings School and Gilead Sciences Inc., and will focus specifically on GS-5734, an experimental antiviral treatment.

授予Baric和Sheahan的合作奖助金建立了Gillings学院和Gilead Inc科学公司(股份有限公司的一种形式,英美法系中股东只承担较少的责任的商业形式)之间的合作关系。

范德比尔特大学医学中心和德克萨斯大学医学分院。

这项合作建立在Gillings学院和Gilead Inc科学公司早期合作的基础上,并将特别关注GS-5734,一种实验性抗病毒治疗。

........

我查看了关于SARS、寨卡、MERS三次全球性大规模呼吸系统突发事件中的相关数据。

ARS 全球共感染8069人,死亡774人(2003年7月11日)美国无死亡案例。

MERS 全球共感染288人,死亡36人,美国无死亡案例。

寨卡 美国本土共感染544人,无死亡病例。

行文至此,若干事实已经逐步清晰。